JP2024540161A5 - - Google Patents

Info

Publication number
JP2024540161A5
JP2024540161A5 JP2024525583A JP2024525583A JP2024540161A5 JP 2024540161 A5 JP2024540161 A5 JP 2024540161A5 JP 2024525583 A JP2024525583 A JP 2024525583A JP 2024525583 A JP2024525583 A JP 2024525583A JP 2024540161 A5 JP2024540161 A5 JP 2024540161A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
halo
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078836 external-priority patent/WO2023077041A1/en
Publication of JP2024540161A publication Critical patent/JP2024540161A/ja
Publication of JP2024540161A5 publication Critical patent/JP2024540161A5/ja
Pending legal-status Critical Current

Links

JP2024525583A 2021-10-29 2022-10-28 Rxfp1アゴニスト Pending JP2024540161A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273290P 2021-10-29 2021-10-29
US63/273,290 2021-10-29
PCT/US2022/078836 WO2023077041A1 (en) 2021-10-29 2022-10-28 Rxfp1 modulators for the treatment of heart failure

Publications (2)

Publication Number Publication Date
JP2024540161A JP2024540161A (ja) 2024-10-31
JP2024540161A5 true JP2024540161A5 (https=) 2025-10-31

Family

ID=84362101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525583A Pending JP2024540161A (ja) 2021-10-29 2022-10-28 Rxfp1アゴニスト

Country Status (7)

Country Link
US (1) US20240417369A1 (https=)
EP (1) EP4423094B1 (https=)
JP (1) JP2024540161A (https=)
KR (1) KR20240095290A (https=)
CN (1) CN118176197A (https=)
ES (1) ES3058993T3 (https=)
WO (1) WO2023077041A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121605099A (zh) * 2023-08-10 2026-03-03 深圳信立泰药业股份有限公司 一种rxfp1受体调节剂及其制备方法和医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US9452973B2 (en) * 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
EP4259605A1 (en) * 2020-12-08 2023-10-18 Astrazeneca AB 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure

Similar Documents

Publication Publication Date Title
JP2024540164A5 (https=)
US6235780B1 (en) ω-cycloalkyl-prostaglandin E1 derivatives
JP2024540163A5 (https=)
JPH07242615A (ja) エーテル置換イソニトリルおよびその製法
JP2024540161A5 (https=)
JP2021534106A5 (https=)
JP2024543013A5 (https=)
JPH08269006A (ja) 一酸化窒素合成酵素阻害作用を有するアニリン誘導体
KR20110013411A (ko) (f-19)-표지된 l-글루탐산 및 l-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법
BE1024380A1 (fr) Phospholipidation d'imidazoquinoleines et d'oxoadenines
JP2019511527A (ja) Pparアゴニスト、化合物、医薬組成物、及びその使用方法
JPS63239259A (ja) 薬剤化合物
JP2025501509A5 (https=)
JP2024546946A5 (https=)
JP2022541453A5 (https=)
JP2021520394A5 (https=)
US6812252B2 (en) Acylsulfonamide derivatives
JP2022522890A5 (https=)
JP2024546943A5 (https=)
JP2025503442A5 (https=)
US5958375A (en) Urea-linked, iodinated bis phenyl compounds for X-ray contrast media
JP2023533037A5 (https=)
AU2012298567B2 (en) New ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases
ES2205536T3 (es) Derivados de pirazina, su preparacion y medicamentos que los contienen.
EP0024924B1 (en) Sydnonimines, their preparation and pharmaceutical compositions containing them